These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32801654)

  • 1. Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use.
    Gilbert MM; Grimes AB; Kim TO; Despotovic JM
    Patient Prefer Adherence; 2020; 14():1237-1250. PubMed ID: 32801654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of romiplostim for pediatric patients with immune thrombocytopenia.
    Al-Samkari H; Grace RF; Kuter DJ
    Ther Adv Hematol; 2020; 11():2040620720912992. PubMed ID: 32523658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.
    Perdomo J
    Immunotargets Ther; 2016; 5():1-7. PubMed ID: 27529057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.
    Grainger JD; Kühne T; Hippenmeyer J; Cooper N
    Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy.
    Buchbinder D; Nugent D; Hsieh L
    Drug Des Devel Ther; 2017; 11():1055-1063. PubMed ID: 28408804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune thrombocytopenia: Pathophysiology and impacts of Romiplostim treatment.
    Semple JW; Schifferli A; Cooper N; Saad H; Mytych DT; Chea LS; Newland A
    Blood Rev; 2024 Sep; 67():101222. PubMed ID: 38942688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
    Kuter DJ; Newland A; Chong BH; Rodeghiero F; Romero MT; Pabinger I; Chen Y; Wang K; Mehta B; Eisen M
    Br J Haematol; 2019 May; 185(3):503-513. PubMed ID: 30793285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study.
    Lee JY; Lee JH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    Thromb Res; 2022 May; 213():114-118. PubMed ID: 35334441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury.
    Watanabe R; Tabayashi T; Tomikawa T; Sagawa M; Anan-Nemoto T; Kimura Y; Takahashi Y; Tokuhira M; Otaki S; Oi H; Sawano M; Sugiyama S; Kizaki M
    Int J Hematol; 2017 Jan; 105(1):100-103. PubMed ID: 27709451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
    Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
    Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice.
    Snell Taylor SJ; Nielson CM; Breskin A; Saul B; Yu Y; Alam N; Eisen M; Hippenmeyer J; Janssens A; Kozak T; Papadaki HA; Selleslag D; Viallard JF; Feistritzer C; Kaiafa G; Kelsh M; Kilpatrick K; Brookhart MA; McGrath LJ
    Adv Ther; 2021 May; 38(5):2673-2688. PubMed ID: 33866516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.